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Abstract 
The control of the formation of crystals in 
biological fluids is one of the most exciting field of 
research involving both organic and biochemical 
areas. Many organisms have evolved mechanisms 
which minimize or avoid the effects of nucleation and 
crystal growth formation. One of the most important 
mechanism is the interaction of specific proteins, called 
inhibitors, with crystals which alters their habits and 
leads to their elimination. This article, focused on 
saliva, pancreatic juice and bile, reviews our present 
knowledge on the structure-function relationships 
existing between these proteins and their ability to 
inhibit the growth of different calcium salt crystals. 
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lntrodu cti on 
In mammals, many biological fluids are 
supersaturated with respect to calcium salts, which are 
carbonate in pancreatic juice and bile, phosphate in 
saliva and mainly oxalate in urine. Supersaturation is 
essential since these minerals are involved in the 
construction of skeletal material, the process of teeth 
mineralization or even specific adsorption to tissues. 
But it also means that calcium salts crystals will 
spontaneously form and grow in those fluids. That is 
why these mineralization processes have to be 
controlled in order to avoid precipitation (nucleation), 
growth and finally aggregation of crystals which might 
induce cell injury or result in the clogging of the ducts 
through which secretion flows. For that purpose, 
organisms developed sophisticated mechanisms 
controlling the deposition of minerals in biological 
tissues. Several small organic and inorganic 
molecules have been shown to inhibit nucleation or 
crystal growth. Now it is clear that in most biological 
fluids, several proteins fulfill the physiological role of 
repressing formation, growth and aggregation of 
calcium crystal salts. The purpose of this paper is not to 
review the evidence documenting the role of proteins 
in the control of crystal growth, but to describe the most 
recent data on the relationship between structure and 
function of these inhibitors in saliva, bile and 
pancreatic juice. The main properties of these protein 
inhibitors are summarized in Table 1. 
Protein Inhibitors 
Inhibitors in saliva 
Human salivary secretion is supersaturated with 
respect to calcium phosphate (CaP) salts which are 
involved in the formation of the dental enamel. 
Supersaturation is quite important in the stabilization 
and protection of enamel and for recalcification after 
demineralization by bacteria (Feagin et al., 1971 ). Yet, 
supersaturation should not result in an excess of 
calcium phosphate precipitation. Early studies on 
calcium phosphate precipitation in saliva showed that it 
was unexpectedly delayed compared to precipitation 
from equivalent synthetic solutions (Rathje, 1956). In 
addition, macromolecular fractions isolated from 
human salivary secretions strongly inhibited 
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Table 1. Main characteristics of protein inhibitors in saliva, pancreatic juice and bile. 
Length Inhibition 




Statherins Statherin (main form), main form (43) CaP 
Statherin SV1, SV2, SV3 (Hay et al., 
(Jensen et al., 1991) 1979; 
Oppenheim 
et al., 1986) 
CaCO3 
(Hay et al., 
1986) 
PRP-1= Protein C, 
Acidic PRP-3= Protein A, PRP-1 and PRP-2 CaCO3 
Praline-Rich- PRP-2, PRP-4, PIF-s, (150), (Saitoh et al., 
Proteins PIF-f PRP-3 and PRP-4 1985; 
(Wong and Bennick, (106), Hay et al., 
1980; PIF-s (150), 1986) 
Schlesinger and Hay, PIF-f (106) 
1979, 1986; 
Wong et al., 1979; 
SALIVA Maeda et al., 1985) 
CCP1=SA-I, S (and S1, 
Type II S2)b=C1 (and C2, CCP1=SA-I (121), ? 
Cystatins C3)=SAP-1, HSP-12=SA- SN (113), 
or Ill, SA, SN SA (121). 
Cysteine- S=SAP-1 (113), 
Containing (AI-Hashimi et al., 1988; HSP-12=SA-III 
Phospho- lsemura et al., 1984, (121) 
proteins (CCP) 1991; 
Shomers et al., 1982a, 
Lamkin et al., 1991) 
Histatin1 (neutral HRP) 
Histatins or =HRP=HRP-1 =PPb HRP (38) inactive for 
Histidine-rich Histati n 2=p hosphory lated CaP 
polypeptides form of Histatin1 (Oppenheim 
(HRP) et al., 1986) 
(Oppenheim eta!., 1986, 
1988; Peters and Azen, 
1977; Baum et al., 1977; 
Azen, 1978; Sabatini and 
Azen, 1989) 
PANCREATIC Pancreatic Lithostathine main form (144) CaCO3 
JUICE (Bernard 
et al., 1992) 
BILE APF/CBP/CRP, all ? CaCO3 
probably identical (Shimizu et al., 
1989; 
Oki do et al., 
1992) 
?: nkn wn r · a: wi h i i . b. . u o o not tested, t outs gnal pept de, . phosphorylated forms of S 








(Hay et al., 
1979; 
Oppenheim 
et al., 1986) 
CaP 
(Hay et al., 
1979; 1984; 





Cystatins S, S1, 
SN: 
(hydroxyapatite; 










et al., 1992) 
CaCO3 (Okido 
et al., 1992) 
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ca2+.blndlng cDNA cloning Other properties Gene cloning Remarks 
properties 
? Sabatini et al., 1) boundary lubricant of Sabatini et al., chromosomal 
1987 human saliva (Douglas et al., 1990 localization : 
1991) 4q11-13 
(Sabatini et al., 1987) 
2) promotes attachment of 
bacteria to apatitic surfaces 
(Gibbons and Hay, 1988; 
Gibbons et al., 1988) 
Hay et al. (1982), Maeda et al., 1) constituents of the enamel O'Hanlon et al., possible role in 
Bennick et al. 1985 pellicle (Kousvelari et al., 1989 tasting (Azen et al., 
( 1981) Bennick, 1987 1980) 1990) 
PRP-1 and PRP-3 : 2) promote attachment of 
ca2+-binding sites bacteria to apatitic surfaces 
(Bennick, 1976, (Gibbons and Hay, 1988; 
1977) Gibbons et al., 1988) 
1) strong binding to 
? SA-I hydroxyapatite (Shomers et SA and SN present in many body 
(AI-Hashimi et al., al., 1982b, Johnsson et al., (Saitoh et al., fluids 
1988); 1991 a) 1987; Saitoh et (Lamkin et al., 1991) 
2) cystatin SN : constituent of a/., 1991) 
Sand SN the enamel pellicle (Al-
(Bobek et al., Hashimi and Levine, 1989) 
1991) 3) potential anti-bacterial 
activity (Obenauf et al., 1984) 
1) antibacterial and antifungal 
? Sabatini and activities (MacKay et al., probably only present in 
Azen, 1989 1984; Oppenheim et al., encoded by two salivary tissues 
1986, 1988: Xu et al., 1991) genes Pb and (Sabatini et al., 1989) 
2) H RPs 1-2 : effects on PPb 
aggregation and viability of 
some bacteria strains (Payne (Azen et al., 
eta!., 1991) 1978, Peters 
3) histatin levels increased in and Azen, 1977) 
AIDS patients (Atkinson et al., 
1990) 
No Giorgi eta!., 1989 Watanabe et al., 
1990 
1) promoter of cholesterol 
highly suspected No precipitation (Domingo et al., No 
(Shimizu et al., 1992) 
1989) 2) tighly bound to bilirubin 
(Shimizu et al., 1989; 
Martigne et al., 1985) 
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Abbreviations 
APF : Anionic-Polypeptide Fraction; CaC03 : 
Calcium carbonate; CaP : Calcium phosphate; CBP : 
Calcium-Binding Protein; CCP : Cysteine-Containing 
Phosphoprotein or Cystatin; CRP : Calcium-
Regulatory Protein; DCPD : Dicalcium phosphate 
dihydrate; HAP : Hydroxyapatite; kb : kilobase; kDa : 
Kilodalton; Mr: Molecular weight; PRP: Praline-Rich 
Protein; PSe : Phosphoserine; PSP : Pancreatic 
Stone Protein; SOS-PAGE : Sodium Dodecyl-Sulfate-
Polyacrylamide Gel Electrophoresis. 
precipitation from supersaturated calcium phosphate 
solutions (Gron and Hay, 1976). This is essentially due 
to the presence of at least four types of proteins in both 
parotid and submandibular gland secretion : proline-
rich-proteins, statherins, cystatins and histatins. These 
four groups of salivary proteins are members of 
superfamilies of related proteins which have evolved 
by different splicings or post-translational processings. 
The first two are well-kown proteins, studied for more 
than 20 years, whereas the discovery of the inhibitory 
activity of the two last ones is more recent. 
The statherins. Statherin, from the greek 
statheropio, meaning "to stabilize", has been 
investigated and purified by Hay ( 1973). The first 
observations on human statherin showed that it 
adsorbed selectively onto hydroxyapatite and dental 
enamel and was by far the most abundant protein 
found in hydroxyapatite-adsorbed fractions from saliva 
(Hay, 1973). Statherin is constituted by a 
heterogeneous population since sequential 
chromatography of hydroxyapatite-adsorbed salivary 
proteins resulted in the purification of several statherin 
variants. It was eventually shown that multiple forms 
of statherin derived from post-translational 
modifications and/or alternative splicing of a single 
gene (Jensen et al., 1991). The biological significance 
of these variants is not understood. The parent 
molecule is a phosphoprotein of 43 amino acid 
residues with a molecular weight of 5380, and an 
acidic isoelectric point of 4.22. A striking feature is its 
unusual amino acid composition: 25% are acidic 
residues (aspartate and glutamate), 25% are aromatic 
residues, mainly tyrosine, and praline accounts for 
16% of amino acids (Schlesinger and Hay, 1977). 
Furthermore, its sequence shows that five of the six 
negatively charged residues occur in the NHrterminal 
peptide while the carboxy-terminal two-third of the 
protein is quite uncharged and relatively hydrophobic 
(Schlesinger and Hay, 1977). At physiological 
concentrations, statherin is able to inhibit crystal 
growth and nucleation of calcium phosphate salts, 
unlike praline-rich-proteins (Schlesinger and Hay, 
1977; Hay et al., 1979). The detailed mechanisms by 
which statherin (or other proteins) inhibit nucleation is 
not well understood. It is generally believed that the 
protein binds to the first embryo crystals, thereby 
delaying precipitation. In some cases, the formation of 
these crystals is rate limiting, especially in the case of 
calcium phosphate precipitation (which facilitates the 
arrest of ttiP.ir growth). Because of the peculiar 
distribution of amino acids in its sequence, many 
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attempts have been made to localize the active 
segments of statherin in both inhibition of nucleation 
and precipitation of calcium phosphate crystals. 
Removal of the carboxy-terminal half of the molecule 
resulted in a 75% reduction of its ability to inhibit 
nucleation, but did not affect its ability to inhibit crystal 
growth. Surprisingly, removal of residues 10-18 and 7-
18, leaving intact both amino-terminal phosphoserines, 
considerably enhanced inhibition of crystal growth 
compared to the parent molecule. This function 
appears entirely localized to the NH2-terminal portion 
of the molecule. This could be explained by the fact 
that smaller fragments have a better access to growth 
sites and are more easily adsorbed onto crystal 
surfaces. Conversely, the inhibitory activity of the NH2-
terminal segments, resulting from protease cleavage, 
on spontaneous precipitation from supersaturated 
solution is reduced compared to the parent molecule. 
This suggests that the carboxy-terminal segment plays 
an important role in the inhibition of nucleation, 
probably by stabilizing the interactions with embryo 
crystals since, by itself, it is without activity (Hay et al., 
1979). In order to assess the importance of the 
phosphoserines, Schlesinger and coworkers (1987) 
synthesized the dipeptide phosphoseryl-
phosphoserine. It was shown to substantially inhibit 
both nucleation and crystal growth, although less than 
the parent molecule. These first attempts to correlate 
structure and function were recently completed by 
systematic analysis. For this purpose, Raj et al. ( 1992) 
synthetized several fragments of statherin. They 
showed first that aspartic acid residues were very 
important in binding and crystal growth inhibition, more 
than phosphoserines. Moreover, they found a good 
correlation between the possible alpha-helix structures 
of acidic NH2-terminal fragments and their capacity to 
bind hydroxyapatite (HAP) surfaces. As shown by 
circular dichroism experiments, the central and COOH-
terminal fragments appear more flexible, adopting 
different conformations depending on the solvent. This 
might reflect the adaptability of the molecule to different 
physiological conditions which optimizes orientation of 
the NH2-terminal part towards the growth faces of the 
crystals. 
The acidic proline-rich-proteins (PRPs\. Amino 
acid analysis of human total salivary proteins revealed 
an unusual content in praline (up to 33%) of total 
amino acids (Leach et al., 1967). The fact that amylase, 
which accounts for more than 30% of parotid and 
submandibular secretory proteins, contains few 
pralines, led some authors to investigate the proteins 
with a high content of praline which were referred to as 
proline-rich-proteins (PRPs). This superfamily can be 
divided into three groups : glycosylated, basic and 
acidic-PRPs (Mandel et al., 1965; Bennick, 1975; 
Levine and Keller, 1977). Some members may also be 
phosphorylated. Within these groups, binding to HAP 
and inhibition of calcium phosphate precipitation are 
only associated with acidic-PRPs (Hay, 1973; Bennick 
and Cannon, 1978). Although these proteins strongly 
inhibit crystal growth of calcium phosphate, they do not 
inhibit nucleation, contrary to statherin (Hay et al., 
1979; Moreno et al., 1979; Hay et al., 1984; 
Oppenheim et al., 1986). Since saliva is 
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supersaturated with respect to calcium phosphate 
salts, it has been proposed that they prevent unwanted 
deposition of these salts onto tooth surfaces by 
adsorbing to calcium phosphate surfaces, providing a 
protective and reparative environment to dental 
enamel (Hay et al., 1979). Four acidic proteins have 
been isolated and named PRP1-4 (Oppenheim et al., 
1971). At the same time, other investigators 
independently described the acidic-proline-rich 
proteins and named them differently which resulted in 
a certain confusion. The primary structures of these 
four proteins have been reported : PRP-1 which is 
identical to Protein C (Wong and Bennick, 1980), PRP-
2 (Schlesinger and Hay, 1986), PRP-3 which is 
identical to Protein A (Wong et al., 1979), and PRP-4 
(Schlesinger and Hay, 1979). PRP-1 and.-2 are 
composed of 150 residues, their sole difference being 
that residue 4 is Asn in PRP-1 and Asp in PRP-2 
(Schlesinger et al., 1977). Similarly PRP-3 and -4 are 
composed of 106 residues, which are identical to the 
106 NH2-terminal amino acids of PRP-1 and PRP-2 
respectively and probably derive from them by post-
translational modification (Karn et al., 1979; Wong et 
al., 1983). In addition, Maeda and coworkers (1985) 
reported the cDNA sequence of two acidic-PRPs, PIF-s 
and PIF-f. PIF-s is identical to PRP-1 and PIF-f to PRP-3 
except that they present with an inversion between 
amino acids 4 and 50. Messenger RNA splicing and 
post-translational cleavage must have been involved. 
This is strenghtened by the results obtained by Maeda 
et al. (1985) suggesting that the entire family of PRP is 
coded only by six loci which might have diverged 
during evolution. The biological significance of these 
differences is not yet known. As for statherin, the 
primary structures of acidic-PRPs revealed a number of 
striking features, particularly a high degree of structural 
charge asymmetry. In spite of primary sequences 
similarities, PRPs display some differences in their 
adsorption onto apatic surfaces. For instance, Moreno 
et al. (1982) reported that PRP-1 has a higher affinity 
constant for HAP than PRP-2. A well-studied example 
is given by PRP-1. The NH2-terminal 30 amino acid-
residues of PRP-1 contain 13 of the 16 negatively 
charged amino acids of the protein, including both 
phosphoserines (Pse). From residue 31 to the COOH-
terminal end, the molecule essentially consists of 
proline, glycine and glutamine with the peculiar 
occurence of the sequence Pro-Gln-Gly-Pro-Pro 
(Bennick, 1982; Hay et al., 1988). Consequently, the 
role of the NH2-terminal portion of the molecule must 
differ considerably from that of the COOH-terminal part. 
These features have been extensively studied in terms 
of structure-function relationship. Initial studies 
performed on the various domains of PRPs showed 
that the phosphoserine-containing amino-terminal 30-
residues are responsible for the inhibitory activity on 
crystal growth. Inhibition of HAP-seeded crystal growth 
by both PRPs and their NH2-terminal parts is closely 
related to their capacity for adsorption onto crystal 
surface (Hay et al., 1979; Bennick et al., 1979; Moreno 
et al., 1979, 1982, 1984; Schlesinger and Hay, 1981; 
Aoba et al., 1984). More complete experiments 
revealed that dephosphorylation of the NH2-terminal 
30-residues results in a sharp decrease of the 
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inhibitory activity (Hay et al., 1987). This is not simply 
due to the charges of the phosphoserines since the 
dipeptide PSe-PSe has no activity but rather to a 
change in secondary structure resulting from 
dephosphorylation (Aoba et al., 1984). Thus, the 
structural basis of the inhibitory activity cannot be 
merely limited to the role of residues. Other 
experiments conducted with PRP-3 have shown that 
the adsorption of the molecule onto crystal surface is 
an endothermic process, driven by an increase of 
entropy, i.e. a maximum disorder in its structure 
(Moreno et al., 1982). This disorder can be translated 
in terms of electrical charges, hydrophilicity and 
distribution of these charges along the molecule. In 
other words, these characteristics are derived from the 
tridimensional structure of proteins which governs 
interactions with the HAP growing surfaces, more than 
the primary sequence of amino acid residues. 
The cystatins. Human cysteine proteinases are 
involved in the intracellular catabolism of proteins. 
They interact specifically with inhibitors called cysteine 
proteinase inhibitors or cystatins. They represent a 
superfamily divided into three families : type I is 
represented by stefins essentially found within cells, 
proteins of type II are found in several tissues and also 
in biological fluids such as urine and saliva (Barrett, 
1987), type Ill is the kininogen family present in blood 
plasma. Type II cystatins contain about 115-
120 aminoacids, with two disulfide bridges in their 
carboxy-terminal region. They were also designated as 
cysteine-containing phosphoproteins (AI-Hashimi et 
al., 1988). They include several sub-classes of 
proteins : the acidic cystatins S1, S2 and S, previously 
known as SAP-1 (lsemura et al., 1984). They were also 
named C1-C3 by Shomers et al. (1982a). Cystatins S, 
S1 and S2 are identical in amino acid composition and 
N-terminal sequence. They probably differ only by their 
degree of phosphorylation (Johnsson et al., 1991 a; 
lsemura et al., 1991 ). The Sand S1 forms are the most 
abundant whereas S2 is very rare. The non-
phosphorylated neutral cystatin SN (lsemura et al., 
1986) is very similar to the cystatin SA-I which shows 
only an additional octapeptide in the NH2-terminal 
region (AI-Hashimi et al., 1988). Cystatin SA-I 
therefore appears to be a larger form of cystatin SN. It 
is also the case with cystatin HSP-12 (SA-Ill; Lamkin 
et al., 1991) which seems identical to cystatin S except 
for the presence of a NH2-terminal octapeptide (Hawke 
et al., 1987). It is quite probable that cystatin S and SN 
resulted from proteolytic cleavage of cystatins HSP-12 
and SA-I, respectively. Comparing amino acid 
sequences of cystatins S, SA and SN revealed a very 
high degree of similarity (around 90%; lsemura et al., 
1987). As for the other inhibitors in saliva, their 
sequence was rather acidic in the NH2-terminal part 
with a central region more basic. Yet, at variance with 
the other inhibitors, their carboxy-terminal portion was 
also acidic. Cystatins from type II bind strongly to HAP 
(Shomers et al., 1982b). In addition, AI-Hashimi and 
Levine ( 1989) detected in vivo the presence of 
cystatin SN in the enamel pellicle. Using the dicalcium 
phosphate dihydrate (DCPD) assay described by Hay 
and Gron (1976), Shomers et al. (1982b) were able to 
show that CCP (i.e., the C1, C2 and C3 forms) inhibited 
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the transformation of DCPD crystals into basic calcium 
phosphate salts. Johnsson et al. (1991 a) showed that 
cystatins S, S1 and SN adsorbed to HAP with a 
maximum about 30-50% of that found for statherin or 
PRP-3, and with a lower affinity. The phosphorylation of 
S into S1 does not seem to alter the affinity although 
the phosphoserine-containing cystatin S1 appears 
more active in the inhibition of calcium phosphate 
crystal growth than the two others, which are 
themselves twice more active than statherin. In the 
case of the S1 form, this could be explained by a better 
binding to HAP since phosphocitrate, which is a potent 
inhibitor of calcium phosphate crystal growth, strongly 
adsorbs to HAP owing to its phosphate groups 
(Johnsson et al., 1991 b). It is not clear however how 
molecules with low affinity for HAP (the S forms) might 
present a lower Kd than a molecule with higher affinity 
(the statherin). The larger size of the cystatins (around 
120 amino acids), compared to that of statherin, might 
permit binding at multiple sites and a stronger 
adsorption. The cystatin supeifamily appears as 
complex. Diversity originates from multiple post-
translational modifications of precursors and from 
expression of different genes. It should provide wider 
specificity. For instance, some of the cystatins might be 
involved in the prevention of dental-plaque aggression 
by inhibiting bacterial cysteine proteinases (Obenauf et 
al., 1984). 
The hjstatjns. Histidine-rich-polypeptides (H RPs) 
or histatins are components of the non-immune 
defense system, which includes antibacterial and 
antifungal activities (MacKay et al., 1984; Oppenheim 
et al., 1986, 1988). As with cystatins, they were isolated 
by several investigators leading to a certain confusion 
in their nomenclature (see Table 1 for the 
concordance). One of the HRPs, histatin 1 (HRP), was 
able to bind HAP (Oppenheim et al., 1986). It is a small 
protein of 38 amino acids which differs from the other 
characterized inhibitors by its pl, close to 7.0, and by its 
low praline content. Usin~ a crystal growth assay, 
Oppenheim et al. (1986) showed that it was an inhibitor 
of crystal growth more potent than PRPs (between 1.5 
and 6.5 times higher) but 6 times less active than 
statherin (Hay et al., 1979; Oppenheim et al., 1986). 
Moreover, it does not inhibit spontaneous precipitation 
of calcium phosphate salts (Oppenheim et al., 1986). 
Summary. Praline-rich-proteins, statherins, 
cystatins and histidine-rich-polypeptides play a crucial 
role in the maintenance of oral health by controlling the 
precipitation of calcium phosphate salts onto dental 
enamel. This activity is essentially localized in the NH2-
terminal part of the proteins, at least for statherin and 
the PRPs. The function of the carboxy-terminal region 
is not known. However, adsorption results in the 
presentation towards the oral cavity of basic amino 
acids (or praline) which can bind lectin receptors 
present at the surface of bacteria. For instance, PRPs 
and statherin promote attachment to several important 
bacterial strains as Actinomyces viscosus or 
Bacteroides gingivalis. Consequently, the COOH-
terminal region should play a role in the control of 
bacterial colonization of the teeth (Gibbons, 1980, 
1989; Gibbons and Hay, 1988). Interaction of PRPs 
and statherin with calcite was also evidenced. Some 
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salivary stones have been reported to contain mainly 
calcite in dog and pig (Weaver, 1964; LeGeros and 
Shannon, 1979). This led to the investigation of 
macromolecular inhibitors of calcite precipitation in 
human saliva. Proline-rich-proteins (Saitoh et al., 1985; 
Hay et al., 1986) and statherin (Hay et al., 1986) were 
found to be potential inhibitors of calcite nucleation. It 
is, however, noteworthy that PRPs are not inhibitors of 
CaP precipitation. What is the biological significance of 
these results ? Inorganic phosphate is a potent 
inhibitor of primary calcite precipitation. Its 
concentration in human saliva is much greater than 
required in vitro to inhibit precipitation from 
supersaturated solutions (Hay et al., 1986). Thus, the 
significance of PRPs and statherin as calcite inhibitors 
in human saliva remains questionable. However, in 
dogs, where the phosphate concentration is lower than 
in humans and where calcite-containing calculi have 
been found, inhibition of calcite precipitation by specific 
proteins appears to be of more potential significance. 
Inhibitors in bile 
Bile contains large amounts of lipids which 
include bile salts, phospholipids and sterols (Carey 
and Cahalane, 1988), mainly cholesterol monohydrate. 
It also contains bilirubin, a pigment present in the form 
of bilirubinate conjugates (Fevery et al., 1983) and a 
mixture of proteins (Swobodnik et al., 1991 ), mostly 
from plasma such as albumin and lgA. Normal human 
bile is always supersaturated with respect to 
bilirubinate calcium salts (Cahalane et al., 1988) and 
may be supersaturated with respect to cholesterol 
(Admirand and ~mall, 1968) and calcium carbonate 
(Shiffman et al., 1987). The control of these 
supersaturated states therefore appears more complex 
than in saliva or pancreatic juice. Bile salts and 
phospholipids bind cholesterol so that it is maintained 
in micellar solution (Admirand and Small, 1968). A 
defect in the control would allow nucleation of 
cholesterol or calcium carbonate crystals which would 
lead to the formation of gallstones. In fact, the major 
crystalline phase found in most gallstones is 
cholesterol (Sutor and Wooley, 1971 ), together with 
bilirubinate/protein complexes and calcium carbonate 
(CaCO3) or CaP (Bogren and Larsson, 1963; Been et 
al., 1979; Malet et al., 1986; Palmer, 1987; Ostrow, 
1990). Several constituents of bile are involved in the 
stabilization of supersaturation, i.e. inhibitors of 
cholesterol precipitation (Holzbach et al., 1984; Busch 
et al., 1991 ), CaCO3 (Sutor and Percival, 1978; 
Sciaretta et al., 1984) and CaP (Sutor and Percival, 
1976). These components are retained by membranes 
with 1 O kDa cut-off, suggesting that they are 
macromolecules, among which proteins appear to 
play a major role (eusch et al., 1991 ). For instance, 
apolipoproteins A-I and A-II inhibit nucleation of 
cholesterol in model systems of supersaturated bile 
(Kibe et al., 1984). Since bile is also supersaturated in 
CaCO3, some investigators have focused on the 
existence of proteins controlling calcium carbonate 
precipitation in bile. 
Calcium-bindinc;i-protejn (CB P)/C a lei um-
rec;iulatory protein (CRP\ L Anionic polypeptide fraction 
.(Affl. There are two main types of gallstones : 
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cholesterol and black pigment stones. Both contain 
calcium salts and a black polymer of derivatives of 
bilirubin (Ostrow, 1990). CBP was purified from 
cholesterol gallstones by Shimizu et al. (1989) 
whereas CRP was purified from black pigment 
gallstones (Okido et al., 1992). These small proteins 
(less than 6 kDa) have almost identical 
characteristics : they have a high content in acidic 
(about 20% of aspartate and glutamate) and 
hydrophobic (about 50%) amino acids residues and a 
low content in basic residues (between 7 and 8%). 
Moreover, both proteins are tightly bound to a pigment, 
presumably bilirubin. This pigment, which is the final 
product of heme catabolism, is conjugated with 
carbohydrates, transported in the liver and excreted 
into bile (Kuenzle et al., 1976). It protects lipids from 
oxidation. This pigment cannot be fully dissociated 
from the protein by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SOS-PAGE) or by 
classical desalting procedures suggesting a covalent 
binding as delta-bilirubin is to plasma albumin (Weiss 
et al., 1983). CBP and CRP also present with the same 
UV absorption spectrum. Both are inhibitors of CaCO3 
precipitation (Shimizu et al., 1989; Okido et al., 1992) 
and crystal growth (Okido et al., 1992), with similar 
inhibitory parameters. These results strongly suggest 
that they are closely related if not identical. It is 
noteworthy that proteins act even in the presence of 
bilirubin. The amino acid involved in the binding of the 
pigment is assumed to be lysine (D. Ostrow, personnal 
communication; Mir et al., 1992), a basic amino acid. 
This suggests that the protein, which is amphipathic as 
the other inhibitors of crystal growth, contains several 
domains. The acidic part could be involved in the 
control of crystal growth, whereas the basic domain 
could be responsible for the binding of bilirubin and the 
hydrophobic core would interact with lipids. Several 
years ago, Martigne et al. (1985) reported the isolation 
of an anionic polypeptide fraction (APF) from the 
human gallbladder bile (Lafont et al., 1977). This 
fraction consisted of a small polypeptide of about 
6.5 kDa, highly acidic, and tightly bound to bilirubin. It 
inhibited CaCO3 precipitation in vitro (Lafont et al., 
1991 ). APF was also detected in black pigment 
gallstones (Martigne et al., 1988). Taken together these 
results suggested that APF and CBP/CRP could be 
related. Epitope mapping and immunological-cross 
reactions actually confirmed that both proteins were 
very similar if not identical (Domingo et al., 1992). APF 
shared some epitopes with apolipoprotein A-1, a 
protein present in bile in large amounts, which is an 
inhibitor of cholesterol precipitation (Kibe et al., 1984). 
APF/CBP interacts with cholesterol/lecithin vesicles 
and promotes the nucleation of cholesterol from model 
biles (Domingo et al., 1992). It is the first protein in bile 
and gallstones reported to interact with calcium salts 
and cholesterol, as an inhibitor or a promoter of 
nucleation. Thus, it probably plays a key role in the 
formation of both pigment and cholesterol gallstones. 
The inhibitor of pancreatic juice ; lithostathine 
The organic matrix associated with CaCO3 in 
pancreatic stones obtained from patients presenting 
with chronic calcifying pancreatitis is mostly made up of 
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a single protein (De Caro et al., 1979; Guy et al., 1983), 
originally called the "pancreatic stone protein" (PSP). 
The specific association of that protein with CaCO3 
suggested that it could be the inhibitor involved in the 
control of crystal growth, which was eventually 
demonstrated (Scheele, 1984). The name "PSP" 
turned out to be misleading, however (Multigner et al., 
1983), after large amounts of the protein had been 
found in normal human pancreatic secretion. It was 
recently changed to "lithostathine" with reference to the 
protein capacity for inhibiting CaCO3 crystal growth 
(Sarles et al., 1990). The first information on 
lithostathine structure was obtained from the protein 
extracted from stones (lithostathine C). Structure of the 
secretory forms was established later and was 
confirmed by data obtained from RNA sequencing. 
Lithostathine C migrated as a single band on SDS-
PAGE, with an apparent molecular weight (Mr) of 
15,000 (De Caro et al., 1984). Analysis of the protein 
by isoelectric focusing revealed four bands in the 
acidic region of the gradient (pl : 5.1, 5.3, 5.5 and 5.8), 
indicating charge heterogeneity. Amino acid 
composition of lithostathine C showed high contents in 
acidic amino acids and the presence of three 
phosphorylated residues. Sequence of 40 amino acids 
from the amino-terminal end did not show homology 
with other protein sequences available at the time. In 
addition, antibodies raised to lithostathine C revealed 
the presence of a related protein in normal pancreatic 
juice but did not cross react with any other secretory 
component. The same antibodies were used to 
immunolocalize the protein in pancreas by electron 
microscopy and showed a positive signal only in the 
secretory compartments of acinar cells. Based on 
immunological techniques, lithostathine therefore 
appeared as a previously unrecognized component of 
pancreatic secretion (Lechene de la Porte et al., 1986). 
Lithostathine immunopurified from juice migrated as 
five bands on SOS-PAGE, with Mr ranging from 15,000 
to 19,000 (Montalto et al., 1986). The secretory forms of 
the protein were called lithosthatine S and numbered 
from 1 to 5 starting from the lowest Mr. The protein 
represents 5-10% of total secretory protein (De Caro et 
al., 1984). The secretory forms of the protein with a Mr 
higher than 16,000 (lithostathines S2-s) could be 
analyzed after separation from the S1 form (Mr= 
15,000) by ion exchange chromatography. They had 
the same protein backbone whose 144 amino acids 
were sequenced (De Caro et al., 1987; 1989). Amino 
acid composition was characterized by a high 
percentage of Asp, Glu and Ser. Three disulphide 
bridges were localized in positions 14-25, 42-140 and 
115-132 (Rouimi et al., 1988). A complex glycan 
containing fucose, galactose, mannose, N-acetyl 
glucosamine, N-acetyl galactosamine and N-acetyl 
neuraminic acid was linked to the threonine in position 
5 (De Caro et al., 1989). The rest of the molecule was 
apparently not glycosylated. Solubility of the S2-s forms 
was above 1 mg/ml and was not notably affected by pH 
in the 2.0-1 o.o range (De Caro et al., 1989; Gross et al., 
1985). The complete amino acid sequence. of 
lithostathine S1 (133 residues) was also determined 
(De Caro et al., 1989). It corresponded to the C-
terminal end of the S2-s polypeptide, starting from the 
J.M. Verdier, B. Dussol, Y. Berland, J.C. Dagorn 
lie in position 12. Hence, lithostathine S1 derives from 
lithostathine S2-s by trypsin-like hydrolysis of the Arg-
lle bond in position 11-12 of the S2-s polypeptide 
(Rouimi et al., 1987). Contrary to lithostathines S2-s, 
solubility of the S1 form depends on pH. Below pH 4 
and above pH 9.5, solubility is more than 1 mg/ml and 
decreases to less than 0.1 mg/ml at neutral pH 
(Montalto et al., 1986; Gross et al., 1985). When 
lithostathine is purified from pancreatic juice collected 
over a mixture of protease inhibitors, the S1 form is 
generally absent. The true secretory forms of 
lithostathine are therefore the S2-s torms, 
lithostathine S1 being eventually formed in juice by 
cleavage of the S2-s polypeptide. The polymorphism of 
the S2-s forms remains to be explained. Cloning and 
sequencing the lithostathine mRNA confirmed that the 
protein was encoded by a single transcript and that the 
amino acid sequence of the encoded protein was 
identical to the sequence previously determined for the 
S2-s polypeptide (Giorgi et al., 1989). These results 
suggested that polymorphism of the S2-s forms was 
caused by post-translational maturation of a single 
polypeptide. Involvement in polymorphism of the 
glycan borne by the NH2-terminal peptide was 
demonstrated (De Caro et al., 1989). The biological 
significance of the polymorphism remains obscure. 
Demonstration that CaCO3, the constituent of stones, 
was in supersaturated concentration in normal 
pancreatic juice led to the corollary that an inhibitor of 
CaCO3 crystal growth had to be present in juice. Such 
an inhibitor must interfere with crystal nucleation or 
growth. The interaction of lithostathine with both steps 
was studied in vitro (Bernard et al., 1992). 
Lithostathines S2-s did inhibit nucleation, a significant 
effect being already observed at a concentration of 
1.5 µM (30 µg/ml). Neither the S1 form nor albumin or 
other secretory proteins showed any inhibition. 
However, lithostathine S2-s at a concentration of 
1 .5 µM significantly inhibited CaCO3 crystal growth, 
contrary to the other pancreatic proteins tested. Binding 
to crystal growth sites occured with a Kd= 0.9 x 10-6 M. 
The S1 form being inactive, it was very likely that the N-
terminal undecapeptide was involved in inhibition. In 
fact, the purified peptide was active, with a Kd= 3.1 x 
10-6 M for growth sites, very similar to the Kd of the 
complete molecule. Activity was abolished by treatment 
of the polypeptide with the V8 protease. The 11 
aminoacids of the N-terminal end of lithostathine 
therefore contain the entire inhibitory site. The complex 
glycan linked to the threonine in position 5 of that 
peptide is not involved in the active site since a 
synthetic undecapeptide identical to the natural one 
but not glycosylated was equally active (Bernard et al., 
1992). Antibodies to human lithostathine could detect 
the presence of related components in the pancreatic 
juice or homogenate of other mammals including rat, 
dog, cow, monkey and pig (Bernard et al., 1991). 
Inhibitory activity was demonstrated in dog and rat. The 
rat protein was studied in more detail and compared to 
human lithostathine (Adrich et al., 1989). The structures 
of the N-terminal peptides were very similar and an 
Arg-lle bond was also present in position 11-12 of the 
native molecule. The rat peptide was however not 
glycosylated and the protein migrated on SOS-PAGE 
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with a single Mr of 17,000. As in human, the native form 
was very soluble and the S1 equivalent generated by 
trypsin hydrolysis had much limited solubility at neutral 
pH (Adrich et al., 1989). Molecular biology data 
showed that human and rat lithostathines have the 
same length and an overall amino acid identity of 70% 
(Rouquier et al., 1991 ). Demonstration that lithostathine 
is inhibitor of CaCO3 crystal growth in vitro (Multigner 
et al., 1983; Yamadera et al., 1990; Bernard et al., 
1992) led to the hypothesis that the protein is involved 
in the control of crystal growth in juice. As a 
consequence, any circumstance leading to diminished 
lithostathine activity is suspected to increase the risk for 
stone formation into the ducts. In some patients 
presenting chronic calcifying pancreatitis, one should 
therefore find such a decreased activity. 
Concentrations of lithostathine mRNA in the pancreas 
of healthy individuals and patients presenting with 
chronic calcifying pancreatitis were compared (Giorgi 
et al., 1989). It was in average 2.3 times lower in 
patients. In agreement with reduced synthesis, 
immunolocalization of lithostathine in zymogen 
granules by electron microscopy evidenced a reduced 
signal in patients with chronic calcifying pancreatitis 
(Lechene de la Porte et al., 1986). Decreased amounts 
of lithostathine were also observed in the juice of 
patients (Multigner et al., 1985; Provensal-Cheylan et 
al., 1990) The messenger RNA encoding human pre-
lithostathine was cloned from a pancreatic cDNA 
library and sequenced (Giorgi et al., 1989). The 498 
nucleotides of coding sequence corresponded to a 
preprotein of 166 amino acids. Sequence of the mature 
protein was found starting at residue 23, without 
discrepancy with the sequence already determined. 
The 22 N-terminal amino acids presented with the 
structural features of signal peptides necessary for 
exocrine proteins to enter the secretory pathway. The 
organization of the lithostathine gene was established 
by Watanabe et al. (1990). It spans approximately 3 kb 
and is composed of 6 exons and 5 intrans. 
Lithostathine is also expressed in tissues other than 
the exocrine pancreas, in conditions where control of 
crystal growth does not seem necessary such as 
during dedifferentiation of colonic cells or regeneration 
of pancreatic islets. The protein might therefore serve 
another function which remains to be elucidated. 
Conclusions 
Most studies regarding protein inhibitors of crystal 
growth have underscored their amphipathic structure. 
All of them are organized into hydrophilic and 
hydrophobic domains. The charged acidic region 
possesses an affinity for the charged crystal and tends 
to coat its surface, whereas the hydrophobic region, 
oriented towards the solution, prevents crystal 
overgrowth. This mechanism seems to apply to all 
proteins inhibiting calcium salts precipitation. Crystal 
growth can nevertheless occur in some instances. A 
qualitative or quantitative defect (Dagorn, 1992) as 
shown for calcium nephrolithiasis (Nakagawa et al., 
1985), might be the main factor in the development of a 
lithiasis. It might also result from an imbalance between 
promoters and inhibitors, resulting from an 
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overproduction of promoters or a deficiency in 
inhibitors. Recent studies have shown that bile 
contains proteins promoting the formation of 
cholesterol crystals (Burnstein et al., 1983; Levy et al., 
1984; Gallinger et al., 1985; Groen et al., 1988; Busch 
et al., 1991 ). In saliva, dentin, a very acidic 
phosphoprotein (Veis and Perry, 1967), promotes the 
formation of HAP (Nawrot et al., 1976). Another 
possibility, observed in human urine with the Tamm-
Horsfall protein (Tamm and Horsfall, 1950), is that a 
protein can either promote or inhibit crystal growth or 
aggregation, depending on physiological conditions 
(Yoshioka et al., 1989; Grover et al., 1990; Hess, 1992). 
All these examples demonstrate the complexity of the 
situation in vivo and the necessity for an adequate 
equilibrium between promoters and inhibitors. 
Characteristics common to these inhibitors are not 
restricted to mammals. The organic matrix of all 
mineralized tissues, including mollusk shells or 
arthropods (Duman and Horwath, 1983; Weiner, 1986), 
contain proteins with a hydrophilic domain very rich in 
aspartate, which inhibit crystal growth (Weiner, 1979). 
For instance, antifreeze proteins, produced by many 
polar and northern coastal fishes during the winter 
season, inhibit ice crystal growth. When the 
temperature reaches two degrees below zero, 
adaptation to external conditions maintains 
homeostasis by lowering the freezing point of body 
fluids and preventing lethal freezing injury (for a review 
see Devries, 1983). Some of them, but not all, have a 
structure different from that of mammalian inhibitors. 
They are too small to be organized into domains, and 
are rich in alanine residues. Surprisingly, alanine 
residues have a strong tendency to form an a-helix in 
water (Chakrabartty et al., 1991) so that they present a-
helical structures in vivo with partial amphiphily (Yang 
et al., 1988). This a-helix shows a dipole moment 
parallel to the helix axis. Interactions of these dipoles 
with those of the water (dipole-dipole interaction) 
inhibit the growth of ice nuclei (Shoemaker et al., 
1987). This is reminiscent of the putative a-helix of the 
acidic NH2-terminal of statherin and suggests that 
inhibitory function cannot be inferred from primary 
sequence analysis only. This is further supported by 
the amino acid comparisons performed with 
mammalian proteins. The mechanisms involved in the 
different systems of crystal growth control are 
apparently similar. Yet, amino acid sequences 
available for the inhibitors do not show any particular 
similarity, suggesting that tridimensional structure is 
probably of paramount importance. Another element of 
complexity results from the variety of crystal forms for a 
single product, depending on its atomic organization. 
For instance, calcium carbonate can crystallize in three 
different systems, with formation of calcite, aragonite or 
vaterite, all of them present in animals. We have 
demonstrated that pancreatic lithostathine could inhibit 
crystal growth of vaterite and calcite (J.M. Verdier, 
unpublished). Experiments done with statherin and 
PRPs showed that they were able to inhibit nucleation 
of calcium carbonate and calcium phosphate salts. 
These results suggest that inhibitors are generally not 
specific and that their structure is compatible with the 
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inhibition of different crystal habits of the same salt. For 
instance, the structure of calcite shows alternate layers 
of calcium and carbonate ions, aligned perpendicularly 
to the c-axis. If the distance between two calcium atoms 
from the crystal fits with the distance between 
carboxylic groups of acidic residues from the protein, 
the oxygen atoms can interact with calcium ions and 
prevent further juxtaposition of earbonate ions by 
disrupting the correct organization. The whole structure 
of the crystal will therefore be highly affected (Weiner 
and Addadi, 1991 ). In fact, studies conducted with 
nephrocalcin, the inhibitor of calcium oxalate crystal 
growth from urine (Nakagawa et al., 1983), have 
shown that the interaction between nephrocalcin and 
calcium oxalate monohydrate crystals resulted also in 
a disturbance of ion stacking along the c-axis by 
binding to the {-1,0, 1} face and disturbing the 
juxtaposition of {-1,0, 1} layers along this axis 
(Deganello, 1991 ). Therefore, it seems that all 
inhibitors interact with crystals by similar mechanisms. 
Many aspects of the control of crystal growth are 
still unresolved and represent an exciting challenge for 
the future. Mechanisms of molecular recognition of 
inorganic surfaces by organic compounds and 
resolution of tridimensional structures of these 
inhibitors should provide important clues to the 
understanding of the processes of crystal growth 
control. 
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Discussion with Reviewers 
J.P. Binette: Do the two lithostathine C and S have 
reaction of identity? The text says "related". Is there any 
difference between the two? 
Authors: Lithostathine C and S are apparently identical 
molecules. The distinction was originally made on the 
basis of localization (lithostathine C in stones, 
lithostathine S as a product of trypsine hydrolysis in 
pancreatic juice). 
J,P, Binette: Would the authors agree to display their 
sagacity and comment on the role of the matrix? 
Authors: This has been well studied in our lab for 
pancreatic lithostathine, which can be inhibitor or 
promotor of crystal growth, depending on the integrity 
of the molecule. The intact protein is inhibitor of crystal 
growth. Yet, upon trypsin hydrolysis, the N-terminal 
undecapeptide (bearing the inhibitory activity) is 
cleaved and the rest of the molecule precipitates at 
neutral pH in the form of fibrils. These precipitates grow 
until complete obstruction of the pancreatic ducts, 
whose epithelium becomes eroded. The resulting 
transsudation increases locally the Ca2+ concentration 
and the protein plugs promote apposition of CaCO3 
crystals. The process ends with the formation of a 
crystalline shell around the plug. 
S, Deganello: Why do you state that inhibitors are not 
specific? Are you not, perhaps, comparing inhibition 
conditionsq which require similar stereochemical 
interactions? 
Authors: We think that inhibitors recognize a specific 
stereochemistry and not a given crystal. In these 
conditions, a given inhibitor can bind different forms of 
the same crystal (e.g., vaterite and calcite for CaCO3 
crystals) or even crystals coming from different salts if 
they present with similar 3D structures. 
S. Deganello: Recent structural data demonstrate that 
THP does not inhibit the growth of COD. According to 
you, under what atomic-molecular conditions could the 
behavior of THP be reversed to that of an inhibitor? Is 
this likely to happen? If so, why? 
Authors; We agree with these data. Recent 
unpublished observations of two groups (including 
ours) seem to corroborate these results, but keeping in 
mind the findings of 8. Hess, the situation concerning 
THP remains questionnable. Sorry, but we do not have 
a clear idea. 
